A detailed history of High Tower Advisors, LLC transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 57,988 shares of CERE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
57,988
Previous 62,076 6.59%
Holding current value
$0
Previous $2.62 Million 9.61%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$38.96 - $42.75 $159,268 - $174,762
-4,088 Reduced 6.59%
57,988 $2.37 Million
Q1 2024

May 06, 2024

SELL
$40.88 - $43.27 $40,880 - $43,270
-1,000 Reduced 1.59%
62,076 $2.62 Million
Q4 2023

Feb 12, 2024

SELL
$20.27 - $42.44 $227,267 - $475,837
-11,212 Reduced 15.09%
63,076 $2.67 Million
Q3 2023

Nov 08, 2023

BUY
$20.26 - $31.91 $5,065 - $7,977
250 Added 0.34%
74,288 $1.62 Million
Q2 2023

Aug 14, 2023

SELL
$23.9 - $35.38 $11,950 - $17,690
-500 Reduced 0.67%
74,038 $2.35 Million
Q1 2023

May 11, 2023

SELL
$22.82 - $35.32 $11,410 - $17,660
-500 Reduced 0.67%
74,538 $1.82 Million
Q4 2022

Feb 08, 2023

SELL
$25.35 - $31.96 $760 - $958
-30 Reduced 0.04%
75,038 $2.37 Million
Q3 2022

Nov 09, 2022

SELL
$25.5 - $41.42 $12,750 - $20,710
-500 Reduced 0.66%
75,068 $2.12 Million
Q2 2022

Aug 10, 2022

SELL
$20.62 - $37.15 $12,372 - $22,290
-600 Reduced 0.79%
75,568 $1.99 Million
Q1 2022

May 12, 2022

BUY
$23.5 - $35.38 $62,980 - $94,818
2,680 Added 3.65%
76,168 $2.69 Million
Q4 2021

Feb 10, 2022

BUY
$29.21 - $44.64 $48,021 - $73,388
1,644 Added 2.29%
73,488 $2.37 Million
Q2 2021

Aug 06, 2021

BUY
$12.56 - $29.69 $66,568 - $157,357
5,300 Added 7.96%
71,844 $1.85 Million
Q1 2021

May 10, 2021

BUY
$12.37 - $17.74 $262,479 - $376,425
21,219 Added 46.82%
66,544 $914,000
Q4 2020

Feb 10, 2021

BUY
$9.82 - $18.27 $445,091 - $828,087
45,325 New
45,325 $752,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.